ERBB2 and breast cancer: Several clinicopathologic factors – such as tumor grade, anatomical extent, presence/absence of lymph node metastases, presence of hormonal receptors and HER2/neu oncogene amplification – have been recognized as having prognostic and predictive value, influencing the management of patients suffering from breast cancer.